Drug intelligence / Profile preview

MGD-1

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

MGD-1 is a synthesized phenylpropionic acid-based hybrid compound developed as a dual PPARα/γ agonist for the treatment of Type 2 Diabetes Mellitus (T2DM). In preclinical in vivo studies using a murine model of non-insulin-dependent diabetes, MGD-1 demonstrated an anti-hyperglycemic effect similar to Pioglitazone, reducing glucose levels from the third hour until the end of the assay. It is considered a safe experimental lead and a potential new molecule for T2DM treatment.

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on MGD-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGD-1.

Explore the full profile